Markets

Results round-up: Glanbia weight-loss drug opportunity, Dalata passenger cap warning and CRH surge

We look at results from three major Irish companies that were released during the week

Albert Manifold, chief executive of CRH, said the recent surge in onshoring activity by global companies has been a major driver of the company’s business over the last year. Picture: Maura Hickey.

Glanbia targets growth on back of miracle weight loss drugs

The widespread use of powerful weight-loss drugs in the US and Europe offers an opportunity for Glanbia, the performance nutrition giant, according to group’s new chief executive Hugh McGuire.

Speaking to the Business Post last week after Glanbia announced a 16 per cent surge in profits to $424 million for 2023, McGuire said the company is optimistic it can benefit from the surging popularity of ...